MA27173A1 - USE OF SUBSTITUTED 3-PHENYL-5-ALCOXY-1,3,4-OXDIAZOL-2-ONE FOR THE MANUFACTURE OF DRUGS WITH INHIBITOR EFFECT ON PANCREATIC LIPASE - Google Patents

USE OF SUBSTITUTED 3-PHENYL-5-ALCOXY-1,3,4-OXDIAZOL-2-ONE FOR THE MANUFACTURE OF DRUGS WITH INHIBITOR EFFECT ON PANCREATIC LIPASE

Info

Publication number
MA27173A1
MA27173A1 MA27804A MA27804A MA27173A1 MA 27173 A1 MA27173 A1 MA 27173A1 MA 27804 A MA27804 A MA 27804A MA 27804 A MA27804 A MA 27804A MA 27173 A1 MA27173 A1 MA 27173A1
Authority
MA
Morocco
Prior art keywords
oxdiazol
alcoxy
drugs
phenyl
substituted
Prior art date
Application number
MA27804A
Other languages
French (fr)
Inventor
Karl Schoenafinger
Stefan Petry
Guenter Mueller
Armin Bauer
Hubert Otto Heuer
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of MA27173A1 publication Critical patent/MA27173A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA27804A 2002-02-28 2004-07-27 USE OF SUBSTITUTED 3-PHENYL-5-ALCOXY-1,3,4-OXDIAZOL-2-ONE FOR THE MANUFACTURE OF DRUGS WITH INHIBITOR EFFECT ON PANCREATIC LIPASE MA27173A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10208986A DE10208986A1 (en) 2002-02-28 2002-02-28 Use of substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one for the production of medicaments with an inhibitory effect on the pancreatic lipase

Publications (1)

Publication Number Publication Date
MA27173A1 true MA27173A1 (en) 2005-01-03

Family

ID=27740557

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27804A MA27173A1 (en) 2002-02-28 2004-07-27 USE OF SUBSTITUTED 3-PHENYL-5-ALCOXY-1,3,4-OXDIAZOL-2-ONE FOR THE MANUFACTURE OF DRUGS WITH INHIBITOR EFFECT ON PANCREATIC LIPASE

Country Status (20)

Country Link
EP (1) EP1482929A1 (en)
JP (1) JP2005519079A (en)
KR (1) KR20040101250A (en)
CN (1) CN1638766A (en)
AR (1) AR038702A1 (en)
AU (1) AU2003210292A1 (en)
BR (1) BR0308045A (en)
CA (1) CA2477005A1 (en)
CO (1) CO5611144A2 (en)
DE (1) DE10208986A1 (en)
HR (1) HRP20040783A2 (en)
HU (1) HUP0500093A2 (en)
IL (1) IL163719A0 (en)
MA (1) MA27173A1 (en)
MX (1) MXPA04007480A (en)
NO (1) NO20044091L (en)
PL (1) PL371310A1 (en)
RU (1) RU2004128932A (en)
TW (1) TW200400026A (en)
WO (1) WO2003072098A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME01942B (en) 2004-06-17 2015-05-20 Cytokinetics Inc Compounds, compositions and methods
CA2585175A1 (en) 2004-10-25 2006-05-04 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising cb1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type i, obesity and related conditions
TW200808321A (en) 2005-12-15 2008-02-16 Cytokinetics Inc Certain chemical entities, compositions and methods
US7825120B2 (en) 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
WO2007078839A2 (en) 2005-12-19 2007-07-12 Cytokinetics, Inc. Compounds, compositions and methods
BRPI0821327A2 (en) * 2007-12-25 2015-06-16 Kissei Pharmaceutical Catechol derivative, pharmaceutical composition containing same, use of catechol derivative, and use of pharmaceutical composition
WO2010074587A2 (en) 2008-12-23 2010-07-01 Bial - Portela & Ca., S.A. 5-o-substituted 3-n-aryl-1,3,4-oxadiazolones for medical use
CN103086859B (en) * 2011-11-08 2015-11-11 清华大学 2,4-dihydroxyl-5,6-replaces-1-halogeno-benzene derivative, its synthetic method and application thereof
US20230271915A1 (en) * 2017-09-01 2023-08-31 Curtin University Synthetic derivatives of oleoyl-lysophosphatidylinositol (oleoyl-lpi) and uses thereof
CN109879839B (en) * 2019-03-12 2023-04-25 沈阳大学 6-piperazinemethyl-7-hydroxy benzofuran compound and medical application thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19942354A1 (en) * 1999-09-04 2001-03-08 Aventis Pharma Gmbh Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one, their manufacture and use in medicinal products
HUP0302772A3 (en) * 2000-03-07 2007-03-28 Sanofi Aventis Deutschland Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one and use thereof for inhibiting hormone-sensitive lipase

Also Published As

Publication number Publication date
BR0308045A (en) 2004-12-21
RU2004128932A (en) 2005-04-10
JP2005519079A (en) 2005-06-30
HUP0500093A2 (en) 2005-04-28
CN1638766A (en) 2005-07-13
AU2003210292A1 (en) 2003-09-09
NO20044091L (en) 2004-09-27
KR20040101250A (en) 2004-12-02
TW200400026A (en) 2004-01-01
MXPA04007480A (en) 2004-11-10
HRP20040783A2 (en) 2005-04-30
IL163719A0 (en) 2005-12-18
EP1482929A1 (en) 2004-12-08
WO2003072098A1 (en) 2003-09-04
CO5611144A2 (en) 2006-02-28
CA2477005A1 (en) 2003-09-04
PL371310A1 (en) 2005-06-13
AR038702A1 (en) 2005-01-26
DE10208986A1 (en) 2003-09-11

Similar Documents

Publication Publication Date Title
LU93320I2 (en) EVEROLIMUS OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
ATE406162T1 (en) PRAMIPEXOLE DELAYED-RELEASE TABLET
NO20053264D0 (en) Device for the production of honeycomb honey.
NO20040933L (en) Novel gamma-secretase inhibitors.
DK1344893T3 (en) Constant force actuator
ATE290837T1 (en) MEDICATION SUPPLY OF THE SUB-TENON
NO20010579L (en) Embodiments on the surface of a body
NO20022645D0 (en) Pharmaceutical superdisintegrant
MA27173A1 (en) USE OF SUBSTITUTED 3-PHENYL-5-ALCOXY-1,3,4-OXDIAZOL-2-ONE FOR THE MANUFACTURE OF DRUGS WITH INHIBITOR EFFECT ON PANCREATIC LIPASE
DE60331753D1 (en) AUTONOMOUS LUBRICANT DISPENSER
ITTO20020157A0 (en) DEPALLETIZING MACHINE.
ITMI20032073A1 (en) PROCEDURE FOR ADJUSTING THE SPEED OF A VEHICLE.
PT1135140E (en) UTILIZATION OF IBANDRONATO FOR THE PROMOTION OF ENDOPROTESES OSSEA INTEGRATION
DE60318661D1 (en) Lubricating the run-flat ring
FI20021674A0 (en) The coating device
FR2837708B1 (en) USE OF 8'-HYDROXYDIHYDROERGOTAMINE FOR THE MANUFACTURE OF A MEDICINE AGAINST MIGRAINE
AU2002366793A1 (en) Improved lilly of the valley aromachemicals
RU2001109481A (en) Antianginal agent
NO20041295L (en) Tieno (1,3) oxazin-4-ones with lipase inhibitory activity
FR2847782B1 (en) ENTOURAGE STRUCTURE OF A LITERARY SOMMIER.
PT9741T (en) PROTECTOR FOR THE BOTTOM OF A SCORE
FR2847783B1 (en) ENTOURAGE STRUCTURE OF A LITERARY SOMMIER.
PT9740U (en) PROTECTOR FOR THE BASIS OF AN ESCORA.
FR2843034B1 (en) JUMP SPRINGBOARD FOR THE ROLLER
ITBO990233A0 (en) EQUIPMENT FOR THE APPLICATION OF A BAND ON THE PERIPHERAL CIRCULAR PROFILE OF AN ARTICLE.